{"id":"ctiv-pv-or-etiv-a-pv","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1631342","moleculeType":"Oligonucleotide","molecularWeight":"9083.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Further research is needed to understand how these drugs work mechanistically.","oneSentence":"cTIV+PV and eTIV_a+PV are investigational drugs with unknown mechanisms of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:07.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational treatment for various conditions"}]},"trialDetails":[{"nctId":"NCT00579345","phase":"PHASE3","title":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Influenza","enrollment":1522}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cTIV+PV OR eTIV_a+PV","genericName":"cTIV+PV OR eTIV_a+PV","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"cTIV+PV and eTIV_a+PV are investigational drugs with unknown mechanisms of action. Used for Investigational treatment for various conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}